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Mucosal vaccineecent outbreaks of HPAI H5N1 in birds and humans brings out an urgent need
to develop potent H5N1 vaccine regimens. Here we present a study on the intranasal vaccination of
recombinant baculovirus surface-displayed hemagglutinin (BacHA) or inactivated whole H5N1 viral (IWV)
vaccine with a recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant in a BALB/c mouse
model. Two groups of mice were vaccinated with different doses (HA titer of log 24 or log 28) of either
HA surface-displayed baculovirus or inactivated whole viral vaccine virus adjuvanted with different doses
(2 μg or 10 μg) of rCTB. The vaccinations were repeated after 28 days. HA speciﬁc serum IgG and mucosal
IgA antibodies were quantiﬁed by indirect ELISA, and serum neutralizing antibody titer were estimated
by hemagglutination inhibition (HI) assay and virus neutralization titer assay. Functional protective
efﬁcacy of the vaccine was assessed by host challenge against HPAI H5N1 strains. The results revealed
that mice co-administered with log 28 HA titer of BacHA vaccine and adjuvanted with 10 μg of rCTB had
a signiﬁcantly enhanced serum IgG and mucosal IgA immune response and serum microneutralization
titer compared with mice administered with unadjuvanted log 24 or log 28 HA titer of BacHA alone. Also
vaccination with 10 μg of rCTB and log 28 HA titer of BacHA elicited higher HA speciﬁc serum and
mucosal antibody levels and serum HI titer than vaccination with log 28 HA titer of inactivated H5N1
virus adjuvanted with the same dose of rCTB. The host challenge study also showed that 10 μg rCTB
combined with log 28 HA titer of BacHA provided 100% protection against 10MLD50 of homologous and
heterologous H5N1 strains. The study shows that the combination of rH5 HA expressed on baculovirus
surface and rCTB mucosal adjuvant form an effective mucosal vaccine against H5N1 infection. This
baculovirus surface-displayed vaccine is more efﬁcacious than inactivated H5N1 inﬂuenza vaccine when
administered by intranasal route and has no biosafety concerns associated with isolation, puriﬁcation and
production of the latter vaccine.
© 2008 Elsevier Inc. All rights reserved.IntroductionHighly pathogenic avian inﬂuenza A virus, H5N1 strains are
currently causing major morbidity and mortality in bird populations
worldwide, especially throughout the Southeast Asia (Fielding et al.,
2007). These outbreaks of H5N1 in poultry and an increasing number
of cases in humans as well, are a cause for concern. Epidemiological
predictions describe this situation as the pre-pandemic stage in the
spread and adaptation of the H5N1 virus to the humans. This brings
out an urgent need to develop potent vaccines against circulatingl rights reserved.inﬂuenza H5N1 strains (Kreijtz et al., 2007). The protective efﬁcacies
of currently licensed H5N1 inﬂuenza split and inactivated egg-derived
whole virus H5N1 vaccines are low against heterologous virus
infection and also show inadequate immunogenicity (Treanor et al.,
2007). Development of a potential vaccine against the circulating HPAI
inﬂuenza viruses during periods of epidemic poses a number of
challenges, such as the need for biosafety containment facilities (Quan
et al., 2007), thorough inactivation and evaluation of its immuno-
genicity. The process is risky, and is usually associated with low yields
of virus in embryonated eggs used for virus propagation (Nicholson et
al., 2001). As an alternative to conventional egg-based and mamma-
lian cell culture produced inﬂuenza vaccine approaches, the produc-
tion of recombinant hemagglutinin subunit vaccine is expeditious,
safe, high-yielding and low in cost (Safdar et al., 2006). Earlier, Treanor
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virus derived rHA subunit vaccine are safe and immunogenic in
humans. Further, the efﬁcacies of rHA based vaccines are comparable
with traditional egg-based vaccines (Wang et al., 2003). Most of the
previous studies have attempted to investigate HA subunit derived
from recombinant baculovirus infected insect cells as a vaccine for
inﬂuenza virus. However, the low solubility of the hydrophobic HA
protein increases the difﬁculty of puriﬁcation (Treanor et al., 2001).
The expression of HA on the surface of baculovirus is an approach to
circumvent the difﬁcult puriﬁcation of HA expressed in insect cells
by other baculoviral strategies. Recombinant baculovirus surface-
displaying hemagglutinin system has advantages such as high stability
and purity than vaccine prepared from recombinant baculovirus
infected insect cells. The surface displaying of HA protein on
baculovirus will enable the rapid production of pre-pandemic and
pandemic vaccines with minimal technical infrastructure at any
location in the world obviating the need for riskful inactivation of
virulent viruses and meticulous protein puriﬁcation processes. More-
over, it has been previously reported that wild-type baculovirus itself
enhances the innate immune responses and provides sufﬁcient
protection against inﬂuenza infection (Abe et al., 2003). The wild-
type AcNPV (Autographa californica nuclear polyhedrosis virus)
baculovirus stimulates the innate immune response through TLR9
and the viral gp64 mediated fusion is necessary for this stimulation
(Abe et al., 2003). The HA surface-displaying baculovirus used in this
study is also capable of transducing the HA protein into the cells of
vaccinated animals. This baculovirus has the HA engineered under a
WSSV ie1 promoter which facilitates a higher level of expression of HA
both in the insect cells and in the transduced mammalian cells (Lu
et al., 2007).
Various strategies are used to enhance the post-vaccination
immune response such as dosage, route of administration, adjuvants
and selection of vaccine strains. Most of the inﬂuenza vaccines have
been administered by intramuscular or subcutaneous injection, whichFig. 1. (A) Serum (1:100) speciﬁc anti-HA IgG antibody response against rH5HA antigen in m
(BacHA 8 or BacHA 4) alone or combinationwith 2 or 10 μg of rCTB as adjuvant. Each point rep
BacHA vaccine [BacHA 8] alone, b-when compared with log 24 HA titer of BacHA vaccine [Bac
HA IgG antibody response against rHA antigen in mice immunized i.n. with log 28 or log 24 H
with 2 or 10 μg of rCTB as adjuvant. Each point represents the arithmetic mean value (n=6)
alone, b-when compared with log 24 HA titer of inactivated whole viral vaccine [IWV 4] alo
1:100) speciﬁc anti-HA IgG antibody response between log 28 HA titer of baculovirus expres
concentration of rCTB as adjuvant. Each point represents the arithmetic mean value (n=6)±
10 μg of rCTB) (⁎pb0.05; ⁎⁎ pb0.02; ⁎⁎⁎ pb0.01).have been shown to be ineffective for the generation of protective
immunity at the mucosal surfaces. Vaccination via an intranasal
mucosal route is an important approach in controlling mucosally
acquired infection like inﬂuenza infection (Ogra et al., 2001). In
addition the intranasal immunization procedure is simple, reliable,
and cheap compared with subcutaneous or intramuscular injection
(Maeyama et al., 2002). Further, mucosal immunizations of particu-
late antigens are known to induce a better immune response than
soluble antigens, in both the mucosal and peripheral immune
compartments. This is because of the bypassing of the NALT (Nasal
mucosa associated lymphoid tissue) by the soluble antigens, thus
not priming a strong local immune response (Wu et al., 1997; Sminia
and Kraal, 1999). This makes the use of VLPs or baculovirus surface-
displayed HA as rational options over soluble HA puriﬁed from
expression systems.
Usually mucosal administration of antigen alone does not induce
an effective and long lasting immunity, therefore a mucosal adjuvant
that can sufﬁciently enhance the mucosal antigen-speciﬁc IgA anti-
body response needs to be used. A number of chemical agents have
been tested to enhance the immunogenicity of mucosally adminis-
tered antigens, but most of them induce an insufﬁcient immune
response (Ogra et al., 2001). In the present study, we evaluate the
efﬁcacy of the intranasal co-administration of recombinant baculo-
virus surface-displayed hemagglutinin (BacHA) genes of three
different H5N1 inﬂuenza virus strains and recombinant cholera
toxin B subunits (rCTB) as a mucosal adjuvant, in mice challenged
with H5N1 virus infection.
Results
Determination of HA speciﬁc antibody levels by indirect ELISA
The HA speciﬁc serum IgG antibody responses across the different
groups, by indirect ELISA, revealed that the group vaccinated with logice immunized i.n. with log 28 or log 24 HA titer of baculovirus expressed HA vaccine
resents the arithmetic mean value (n=6)±SE. (a-when compared with log 28 HA titer of
HA 4] alone, ⁎p–>pb0.05; ⁎⁎p–>pb0.02; ⁎⁎⁎p–>pb0.01). (B) Serum (1:100) speciﬁc anti-
A titer of H5N1 inactivated whole viral vaccine (IWV 8 or IWV 4) alone or combination
±SE. (a-when compared with log 28 HA titer of inactivated whole viral vaccine [IWV 8]
ne, ⁎p–>pb0.05; ⁎⁎p–>pb0.02; ⁎⁎⁎p–>pb0.01). (C) Comparison of the serum (dilution
sed HA (BacHA) vaccine and H5N1 inactivated whole viral vaccine (IWV) with different
SE. (a-when compared with log 28 HA titer of baculovirus expressed HA (BacHA 8 and
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10 μg of rCTB signiﬁcantly enhanced the HA speciﬁc IgG antibody
response after the primary immunization and secondary immuniza-
tion (Fig. 1A) on all time points of testing compared with the groups
vaccinated with log 24 (Pb0.01) or log 28 (Pb0.05) HA titer of BacHA
alone. Also, analysis of assay results on day 42 and 56 showed a
signiﬁcant (Pb0.05) enhancement of the antibody response in the
group vaccinated with log 28 HA titer of BacHA and 10 μg of rCTB
when compared with the group vaccinated with log 28 HA titer of
inactivated whole viral (IWV) vaccine and 10 μg of rCTB (Fig. 1C).
Moreover, log 24 HA titer of BacHA with 10 μg of rCTB also enhanced
the serum HA speciﬁc IgG antibody response to a lesser degree
compared with log 24 (Pb0.05) HA titer of either BacHA vaccine
alone or in combination with 2 μg rCTB (Pb0.05) (Fig. 1A). However,
log 28 or log 24 HA titer of BacHA vaccine with 2 μg of rCTB (Fig. 1A)
or log 28 or log 24 HA titer of IWV vaccine with 2 μg of rCTB (Fig. 1B)
does not elicit a signiﬁcant difference in the HA speciﬁc serum IgG
antibody response compared with log 28 and log 24 HA titer of both
the vaccines alone.
The HA speciﬁc IgA levels in nasal mucosal secretions were
estimated by indirect ELISA with nasal washings. The results showed
that log 28 HA titer of both BacHA and IWV vaccine adjuvanted with
10 μg of rCTB signiﬁcantly (Pb0.02, Pb0.01 respectively) enhanced
the HA speciﬁc mucosal IgA titer compared with log 28 HA titer of
BacHA and IWV vaccine without adjuvant on all the days tested
(Figs. 2A and B). Also, log 28 HA titer of BacHA vaccine with 10 μg of
rCTB showed a signiﬁcant enhancement of the IgA secretion on day
14 (Pb0.05), 28, 42 and 56 (Pb0.01) when compared with log 28 HA
titer of IWV vaccine with 10 μg of rCTB (Fig. 2C). Moreover, log 24 HA
titer of BacHA vaccine with 10 μg of rCTB also enhanced (Pb0.01) the
speciﬁc IgA secretion to a lesser degree compared with log 24 BacHA
alone in all the days tested (Fig. 2A). The results are comparable
with mice co-administered with log 24 HA titer of IWV vaccine and
10 μg of rCTB (Fig. 2C). Either log 28 or log 24 HA titer of both BacHA
and IWV vaccines with 2 μg of rCTB does not enhance the HAFig. 2. (A) Nasal (dilution 1:50) anti-HA IgA antibody secretion against rHA antigen in mice im
or BacHa 4) alone or combination with 2 or 10 μg of rCTB as adjuvant. Each point represents
vaccine [BacHA 8] alone, b-when compared with log 24 HA titer of BacHA vaccine [BacHA
secretion against rHA antigen in mice immunized i.n. with log 28 or log 24 HA titer of H5N1 i
rCTB as adjuvant. Each point represents the arithmetic mean value (n=6)±SE. (a-when com
compared with log 24 HA titer of inactivated whole viral vaccine [IWV 4] alone, ⁎⁎p–>pb0
secretion between log 28 HA titer of baculovirus expressed HA (BacHA) vaccine and H5N1 ina
point represents the arithmetic mean value (n=6)±SE. (⁎pb0.05; ⁎⁎⁎p–>pb0.01).speciﬁc mucosal IgA secretion when compared with unadjuvanted
vaccines.
Comparison of the functional efﬁcacy of the vaccine groups by
hemagglutination inhibition (HI) assay with serum from different
groups of mice
The results revealed that log 28 HA titer of BacHA vaccination with
10 μg of rCTB signiﬁcantly enhanced the systemic immune response in
terms of hemagglutination inhibition (HI) titer of the serum after the
primary immunization and secondary immunization (Fig. 3A) of mice
on any day of testing compared over vaccination with log 24 (Pb0.01)
or log 28 (Pb0.05 or Pb0.01) HA titer of BacHA alone. On day 14 and
28, mice co-administered with 10 μg of rCTB and log 28 HA titer of
BacHA showed a similar pattern of HI titer when comparedwith log 28
HA titer of IWV vaccine with 10 μg of rCTB, whereas on day 42 and 56
the log 28 HA titer of BacHA with 10 μg of rCTB showed a signiﬁcant
difference (Pb0.05 or Pb0.02) of the HI titer when compared with
IWV vaccine at the same dose of antigen (log 28 HA titer) and adjuvant
(10 μg of rCTB) (Fig. 3C). Serum frommice vaccinated with log 24 or log
28 HA titer of IWV vaccine combined with 2 μg rCTB adjuvant did not
have any signiﬁcant difference on the HI titer over non-adjuvanted
vaccination with log 24 or log 28 HA titer of IWV on any day of testing
(Fig. 3B).
Determination of neutralizing antibody levels by serummicroneutralization
assay
The serum microneutralization test also revealed that vaccination
with log 28 HA titer of BacHA with 10 μg of rCTB (Fig. 4A) or IWV
vaccine with 10 μg of rCTB (Fig. 4B) signiﬁcantly enhanced the virus
neutralizing titer against (Pb0.01) H5N1 viral strain compared with
log 28 HA titer of BacHA or IWV vaccine alone. Moreover, log 24 HA
titer of BacHA and IWV vaccine with 10 μg of rCTB also enhanced the
serum viral neutralizing titer to a lesser degree compared with log 24munized i.n. with log 28 or log 24 HA titer of baculovirus expressed HA vaccine (BacHA 8
the arithmetic mean value (n=6)±SE. (a-when compared with log 28 HA titer of BacHA
4] alone, ⁎⁎p–>pb0.02; ⁎⁎⁎p–>pb0.01). (B) Nasal (1:50 dilution) anti-HA IgA antibody
nactivated whole viral vaccine (IWV 8 or IWV 4) alone or combination with 2 or 10 μg of
pared with log 28 HA titer of inactivated whole viral vaccine [IWV 8] alone, b-when
.02; ⁎⁎⁎p–>pb0.01). (C) Comparison of the nasal (1:50 dilution) anti-HA IgA antibody
ctivatedwhole viral vaccine (IWV) with different concentration of rCTB as adjuvant. Each
Fig. 3. (A) Serum hemagglutination inhibition titer of mice immunized i.n. with log 28 or log 24 HA titer of baculovirus expressed HA vaccine (BacHA 8 or BacHA 4) alone or
combination with 2 or 10 μg of rCTB as adjuvant. Each point represents the arithmetic mean value (n=6)±SE. (a-when compared with log 28 HA titer of BacHA vaccine [BacHA 8]
alone, b-when compared with log 24 HA titer of BacHA vaccine [BacHA 4] alone, ⁎p–>pb0.05; ⁎⁎⁎p–>pb0.01). (B) Serum hemagglutination inhibition (HI) titer against H5N1 virus in
mice immunized i.n. with log 28 or log 24 HA titer of H5N1 inactivated whole viral vaccine (IWV 8 or IWV 4) alone or combination with 2 or 10 μg of rCTB as adjuvant. Each point
represents the arithmetic mean value (n=6)±SE. (a-when compared with log 28 HA titer of inactivated whole viral vaccine [IWV 8] alone, b-when compared with log 24 HA titer of
inactivated whole viral vaccine [IWV 4] alone, ⁎p–>pb0.05; ⁎⁎⁎p–>pb0.01). (C) Comparison of the serum HI titer between log 28 HA titer of baculovirus expressed HA (BacHA)
vaccine and H5N1 inactivated whole viral vaccine (IWV) with different concentration of rCTB as adjuvant. Each point represents the arithmetic mean value (n=6)±SE. (⁎pb0.05;
⁎⁎p–>pb0.02).
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vaccines at a dose of log 28 or log 24 of HA titer with 2 μg of rCTB does
not signiﬁcantly increase the neutralization titer compared with the
respective vaccines at corresponding doses with out the rCTB
adjuvant.Fig. 4. (A) Serum microneutralization assay titer in mice immunized i.n. with log 28 or l
combination with 2 or 10 μg of rCTB as adjuvant. Each point represents the arithmetic mea
alone, b-when compared with log 24 HA titer of BacHA vaccine (BacHA 4) alone, ⁎⁎⁎p–>pb
log 24 HA titer of H5N1 inactivated whole viral vaccine (IWV 8 or IWV 4) alone or combin
value (n=6)±SE. (a-when compared with log 28 HA titer of inactivated whole viral vaccin
[IWV 4] alone, ⁎⁎p–>pb0.02; ⁎⁎⁎p–>pb0.01).Infection challenge test with HPAI H5N1 inﬂuenza strains
Four weeks after the second immunization, all groups of mice
(n=6/group) were challenged intra nasally with 10MLD50 of HPAI
H5N1 strains from clade 2.1 and percent survival was recorded. Theog 24 HA titer of baculovirus expressed HA vaccine (BacHA 8 or BacHA 4) alone or
n value (n=6)±SE. (a-when compared with log 28 HA titer of BacHA vaccine [BacHA 8]
0.01). (B) Serum microneutralization assay titer in mice immunized i.n. with log 28 or
ation with 2 or 10 μg of rCTB as adjuvant. Each point represents the arithmetic mean
e [IWV 8], b-when compared with log 24 HA titer of inactivated whole viral vaccine
416 M. Prabakaran et al. / Virology 380 (2008) 412–420progression of infectionwas indicated by varying trends of decrease in
body weight in the different groups. In mice challenged with H5N1
CDC/594/Indonesia/06 strain, the unvaccinated group showed the
most rapid decline in bodyweight, culminating in 100% mortality
within day 4 after challenge. The body weight of succumbed mice
from this group, on day 3, was below 80% of the original body weight
(Figs. 5C and D). The mice from the group vaccinated with log 28 HA
titer of BacHA vaccine containing 10 μg rCTB showed no decrease in
body weight after the challenge (Fig. 5C). The groups that were
vaccinated with log 28 HA titer of BacHA with a lower dose of rCTB
(2 μg) or alone and log 24 HA titer of BacHA with 10 μg rCTB showed
less than 10% loss of bodyweight and from 4 days after challenge the
mice started gradually regaining their bodyweight. The groups of mice
vaccinated with log 24 HA titer of BacHA with a lower dose of rCTB
(2 μg) or alone showed a higher loss of body weight of up to 20%.
However, in mice vaccinated with IWV vaccine, only the groups
adjuvanted with 10 μg rCTB at either log 28 or 24 HA titer of antigen
showed mild decrease of bodyweight (up to 10% and 13.0%Fig. 5. (A and C) Protection of mice from lethal H5N1 viral challenge. Groups of mice (n=6)
baculovirus surface-displayed hemagglutinin (BacHA) vaccine in the presence or absence of t
with a lethal dose of mouse-adapted Indonesian HPAI H5N1 (A/Indonesia/CDC594/2006, clad
5C) throughout a 14 day observation period. The results are expressed in terms of percent su
Protection of mice from lethal H5N1 viral challenge. Groups of mice (n=6) were intranasally
viral (IWV) vaccine in the presence or absence of the rCTB adjuvant. Four weeks after the
Indonesian HPAI H5N1 (A/Indonesia/CDC594/2006, clade 2.1.2) virus (10MLD50). Mice were m
period. The results are expressed in terms of percent survival and percent body weight (atrespectively). The body weight of other groups of mice vaccinated
with IWV vaccine adjuvanted with a lower dose (2 μg) of rCTB or alone
dropped to below 80% of the original body weight around 4 days after
challenge (Fig. 5D). Themortality ﬁgures showed that log 28 HA titer of
BacHAvaccine containing 10 μg rCTB provided 100% protection against
10MLD50 of two H5N1 strains, CDC/594/Indonesia/06 (Fig. 5A) and
TLL/013/Indonesia/06 (Fig. 6A) from clade 2.1. The log 28 HA titer of
IWV vaccine containing 10 μg rCTB provided 100% protection against
TLL/013/Indonesia/06 strain (Fig. 6B), but comparatively lesser
protection (83.3%) against CDC/594/Indonesia/06 strain (Fig. 5B).
Moreover, even a lower dose of log 24 HA titer of BacHA combined
10 μg rCTB provides sufﬁcient protection (83.3%) against the two
different H5N1 viral strains (Figs. 5A and 6A). Baculovirus surface-
displayed vaccine at log 24 or log 28 HA titer alone or combined with
2 μg of rCTB also providesmoderate protection against H5N1 (TLL/013/
Indonesia/06) (66.6% and 83.3% respectively) and CDC/594/Indonesia/
06 strain (83.3% and 83.3% respectively). However, IWV vaccine at
either doses of log 24 or log 28 HA titer alone or combined with 2 μgwere intranasally inoculated two times at 28 days intervals with log 24 or 28 HA titer of
he rCTB adjuvant. Four weeks after the ﬁnal vaccination, mice were intranasally infected
e 2.1.2) virus (10MLD50). Mice were monitored for survival (Fig. 5A) and weight loss (Fig.
rvival and percent of body weight (at the beginning of the trial) respectively. (B and D)
inoculated two times at 28 days intervals with log 24 or 28 HA titer of inactivated whole
ﬁnal vaccination, mice were intranasally infected with a lethal dose of mouse-adapted
onitored for survival (Fig. 5B) and weight loss (Fig. 5D) throughout a 14 day observation
the beginning of the trial) respectively.
Fig. 6. (A) Protection of mice from lethal H5N1 viral challenge. Groups of mice (n=6) were intranasally inoculated two times at 28 days intervals with log 24 or 28 HA titer of
baculovirus surface-displayed hemagglutinin (BacHA) vaccine in the presence or absence of the rCTB adjuvant. Four weeks after the ﬁnal vaccination, mice were intranasally infected
with a lethal dose of mouse-adapted Indonesian HPAI H5N1 (A/Indonesia/TLL013/2006, clade 2.1.3) virus (10MLD50). Mice were monitored for survival throughout a 14 day
observation period. The results are expressed in terms of percent survival. (B) Protection of mice from lethal H5N1 viral challenge. Groups of mice (n=6) were intranasally inoculated
two times at 28 days intervals with log 24 or 28 HA titer of inactivated whole viral (IWV) vaccine in the presence or absence of the rCTB adjuvant. Four weeks after the ﬁnal
vaccination, mice were intranasally infected with a lethal dose of mouse-adapted Indonesian HPAI H5N1 (A/Indonesia/TLL013/2006, clade 2.1.3) virus (10MLD50). Mice were
monitored for survival throughout a 14 day observation period. Results are expressed in terms of percent survival.
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(Figs. 5B and 6B).
Discussion
Our laboratory has previously reported the construction and
characterization of HA0 displayed on the AcNPV baculovirus surface
(Lu et al., 2007). The baculovirus surface-displayed HA retained its
authentic structure as evidenced by hemagglutination and intra-
muscular immunization of this baculoviral HA virus in mice induced
hemagglutination inhibiting serum antibodies, which were capable
of neutralizing H5N1 inﬂuenza virus in cell culture infectivity assays
(Lu et al., 2007). In the present study, we have evaluated the
intranasal co-administration of recombinant baculovirus surface-
displayed HA (BacHA) and recombinant cholera toxin B subunit
(rCTB) as a mucosal adjuvant. The evaluation of HA speciﬁc antibody
response indicate that co-administration of BacHA vaccine with
10 μg rCTB signiﬁcantly enhances the serum IgG antibody response
and hemagglutination inhibition (HI) titer. Although, the HA speciﬁc
antibody response in mice co-administered with log 28 HA titer of
BacHA vaccine and 10 μg of rCTB was comparable to the antibody
response in mice co-administered with same titer of H5N1
inactivated whole viral (IWV) vaccine along with 10 μg of rCTB, on
day 14 and day 28 after 1st immunization, the antibody response
was signiﬁcantly enhanced on day 42 and 56 (day 14 and 28 after
2nd immunization) in the former (Fig. 1C and Fig. 3C). Moreover,
inoculation of mice with log 24 or log 28 HA titer of either BacHA or
IWV vaccine with 10 μg of rCTB enhanced the antibody response at a
dose dependent manner with reference to both HA titer and rCTB
dose. Further, the serum microneutralization test also reveals that
10 μg of rCTB adjuvanted BacHA or IWV vaccine, of HA titer of log 28,
enhanced the virus neutralizing titer against H5N1 viral strain
compared with log 24 or log 28 HA titer of both BacHA or IWV
vaccine alone.
The HA speciﬁc mucosal IgA antibody responses by indirect ELISA
also reveals a similar kinetics to that of serum HA speciﬁc IgG
response in all groups of mice. Mice co-administered with log 28 HA
titer of BacHA vaccine and 10 μg of rCTB elicited a signiﬁcantly highermucosal HA speciﬁc IgA antibody secretion when compared with
unadjuvanted control. However, vaccination with log 28 HA titer of
BacHA vaccine and 2 μg of rCTB induced mucosal HA speciﬁc IgA
antibody secretion which is not statistically different from the
unadjuvanted control (pN0.05) (Figs. 2A and C). These results show
that rCTB enhances the HA speciﬁc mucosal IgA secretion in a dose
dependent manner. The advantage of the induction of mucosal IgA
secretion is that it confers efﬁcient protection against mucosally
acquired infection (Yuki and Kiyono, 2003). Recently, Isaka et al.,
(2008) reported that intranasal co-administration of rCTB, as a
mucosal adjuvant, with inactivated inﬂuenza A and inﬂuenza B virus
in mice stimulates serum IgG and mucosal IgA antibody responses,
and also induces protective immunity against viral challenge. Earlier
studies have reported that intranasal co-administration of rCTB with
currently available vaccines such as tetanus toxoid (Isaka et al., 1998)
and hepatitis B vaccine (Isaka et al., 2001) stimulates systemic IgG
and IgA responses. Moreover, Isaka et al (2004) have also conﬁrmed
that rCTB is non-toxic and a combination of rCTB with Diphtheria
(DPT) vaccine as a mucosal adjuvant could be easily licensed for
human use. Another study also showed that intranasal administra-
tion of rCTB to BALB/c mice showed no distinct local histopatholo-
gical reactions in the nasal cavity (Goto et al., 2000). Wang et al.
(2003) reported that rCTB is a potent adjuvant for mucosal
immunization which directly co-stimulates the antigen-primed CD4
and CD8 T cells. Further rCTB enhances the antigen-speciﬁc CD4 T-
cell-mediated production of interleukin-2 (IL-2), IL-4 and IFN-γ by
four to ﬁve fold increases. Our studies also reﬂect that 10 μg rCTB
adjuvanted BacHA (log 28 HA titer) primed mice show an enhanced
HA speciﬁc secondary immune response after the second immuniza-
tion (Figs. 1A, 2A and 3A) when compared with unadjuvanted BacHA
(log 28 HA titer). This could be ascribed to the effect of rCTB on
antigen-primed CD4 and CD8 T cells.
The overall integrated immunity derived from mucosal compart-
ment and systemic compartment due to the BacHA vaccine,
adjuvanted with rCTB, were assessed by virulent H5N1 virus
challenge. Monitoring after challenge showed that there was no
decrease in the body weight of mice vaccinated with log 28 HA titer
of BacHA with 10 μg of rCTB. In the groups of mice vaccinated with
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of rCTB adjuvant (10 μg) showed less than 10% of loss of body
weight. Also in the mice vaccinated with IWV vaccines adjuvanting
with a higher dose of rCTB (10 μg) provided lesser loss of body
weight (within 13%). The mortality rate results reveal that log 28 HA
titer of BacHA vaccine containing 10 μg rCTB provided 100%
protection against two different strains (Figs. 5A and 6A). However,
log 28 HA titer of IWV vaccine containing 10 μg rCTB provided 100%
protection only against the H5N1 strain clade 2.1.2 and compara-
tively less protection against clade 2.1.3. Moreover, a lower dose of
log 24 HA titer of BacHA combined with 10 μg rCTB also provides
sufﬁcient protection against two different H5N1 viral strains.
Further, a dose of log 28 HA titer or log 24 HA titer of BacHA
vaccine alone or combined with 2 μg of rCTB also provides moderate
protection against H5N1 infection. However, IWV vaccine at a dose
of both log 24 and log 28 HA titer alone or combined with 2 μg rCTB
provides inadequate protection against H5N1 strains. This study
demonstrates that baculovirus surface-displayed recombinant HA
vaccine has high protective efﬁcacy against H5N1 strains and rCTB
considerably potentiates this protective efﬁcacy. These ﬁndings
advocate the pursuing of the baculovirus surface-displayed system
as an inﬂuenza H5N1 vaccine.
Recently, Treanor et al. (2007) reported that baculovirus expressed
trivalent vaccine containing HA from H1N1, H3N2 and inﬂuenza B
provide a safe and immunogenic vaccine in a healthy adult human
population. Abe et al. (2003) reported that intranasal immunization of
recombinant baculovirus expressing the HA gene provides complete
or higher protection against inﬂuenza H1N1 viral infection than
intradermal or intramuscular administration. Moreover, they also
reported that intranasal immunization of wild-type baculovirus alone
also provides sufﬁcient protection from the H1N1 inﬂuenza lethal
challenge. This might be due to the fact that baculovirus envelope
protein, gp64, recognizes TLR9 molecule and thus activates the innate
immune response. Previous studies reported that, baculovirus
induced IFN production in mammalian cells and provide in vivo
protection of mice from encephalomyocarditis virus infection (Gro-
nowski et al., 1999). Further, Abe et al. (2003) reported that
baculovirus alone, stimulates TNF-α, IL-1 α, and IL-1β expression in
primary cultures of rat hepatocytes (Beck et al., 2000) and also
induced the secretion of inﬂammatory cytokines, such as TNF-α and
IL-6 in a murine macrophage cell line.
In the present study, we utilized baculovirus surface expressed
recombinant HA vaccine which was prepared from three different
H5N1 Indonesian strains based on the sequence homology
difference (b96%). These highly pathogenic avian inﬂuenza viral
strains are antigenically distinguishable from the HA of the most of
the H5N1 of clade 2.1. This study highlights that rHA expressed by
baculovirus surface-displaying system are stable and have high
protective efﬁcacy against viral infection. Moreover, rCTB containing
baculovirus expressed recombinant HA elicits strong mucosal IgA
secretion in the respiratory tract and provides efﬁcient protection
against H5N1 infection. The results of the speciﬁc antibody response
are similar after 1st immunization and greater after the 2nd
immunization when compared with inactivated H5N1 inﬂuenza
vaccine produced in chicken eggs. Moreover, mucosal immunity
prevents the onset of infection, rather than the control of infection
provided by systemic vaccination. Future studies will be done to
improve the protective range of this system using appropriate
selection of virus strains for the composition of the vaccine. The
strains will be selected based on the currently circulating H5N1
from the three different clades. The surface-displayed BacHA virus
has the advantages of obviating biosafety issues and tedious
isolation and puriﬁcation of the recombinant HA. Further, the
nasal administration of the vaccine induces a strong mucosal and
systemic immunity and favours easy administration during
emergencies.Materials and methods
Inﬂuenza viruses
The highly pathogenic inﬂuenza A Human H5N1 viruses such as
CDC/669/Indonesia/06 (GeneBank accession no. CY014481), CDC/594/
Indonesia/06 (GeneBank accession no. CY014272) and CDC/329/
Indonesia/06 (Gene Bank accession no. CY014206) were obtained
fromMinistry of Health (MOH), Indonesia and were propagated in the
allantoic cavity of 11 day-old speciﬁc-pathogen-free (SPF) embryonat-
ing chicken eggs at 37 °C. Allantoic ﬂuids were harvested 48 h post-
inoculation. Virus titers were determined using hemagglutination
(HA) assays. The virus was then clariﬁed at 20,000×g for 20min at 4 °C
to remove debris followed by ultracentrifugation of the supernatant at
100,000×g for 2 h at 4 °C and stored at −80 °C. For, mice challenge
studies, HPAI H5N1 strains were also obtained from MOH, Indonesia
and were propagated in embryonating chicken eggs. A region of the
HA gene of the virus present in samples were ampliﬁed by PCR and
sequenced directly and registered as A/Indonesia/TLL013/2006 (Gen-
eBank accession no. EU015415). All experimentswith live viruseswere
performed in a biosafety level 3 (BSL-3) containment laboratory in
compliance with CDC/NIH and WHO recommendations (NIH, 1999
and WHO, 2004) and also were approved by the Agri Veterinary
Authority (AVA) and Ministry of Health (MOH) of Singapore.
Recombinant cholera toxin B subunit (rCTB) was provided by
Shanghai United Cell Biotechnology Co., Ltd. (Shanghai, PR China).
Preparation of recombinant baculovirus subunit vaccine
The generation of the recombinant baculovirus vectors were done
as described before (Lu et al., 2007). WSSV ie1 promoter controlled HA
expression cassette were inserted into the shuttle vector pFastBac1
and integrated into the baculovirus genome within DH10BAC™
according to the protocol of Bac-To-Bac system (Invitrogen). The full
length HA gene (HA0) in our study was ampliﬁed from three different
inﬂuenza H5N1 Indonesia strains (CDC/669/Indonesia/06, CDC/594/
Indonesia/06 and CDC/329/Indonesia/06) in a standard PCR method
(94 °C 20 s, 55 °C 30 s and 72 °C 2 min for 30 cycles) with a primer set
of HA Forward SalI 5′-ACGCGTCGACATGGAGAAAATAGTGCTTCT-3′ and
HA Reverse NotI 5′-AGTTTGCGGCCGCTTAAATGCAAATTCTGCATTG-
TAAC-3′. The vaccine strains for this study were selected based on
the sequence homology differences (b96%) to the available strains
from clade 2.1. The Bacmid transfected into SF9 cells and the
supernatant containing recombinant baculovirus were harvested at
96 h post-infection. The supernatant was centrifuged at 1000×g for
5 min. Virus titers were determined by standard plaque assays with
SF9 cells according to baculovirus construction protocol (Invitrogen,
No.10359). The vaccine was prepared based on the hemagglutination
titer (HA) of log 24 and log28.
Preparation of inactivated whole viral vaccine
The H5N1 inactivated whole virus (IWV) vaccine was prepared by
treating H5N1 virus (CDC/669/Indonesia/06) with 0.025% formalin at
4 °C for 72 h. The virus was then puriﬁed and used as a reference
vaccine for this study. The complete loss of infectivity of the
inactivated virus was determined by inoculation and titration of
vaccine preparation in eggs.
Vaccine trial
Six-week-old female inbred BALB/c mice were used in all
experiments. Thirty six mice per each experimental group (n=36/
group) were vaccinated intranasally two times at a regular interval of
28 days with 20 μl containing log 24 or log 28 HA titer of puriﬁed
baculovirus surface-displayed hemagglutinin vaccine or inactivated
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(PBS), pH 7.4, adjuvanted with 2 μg, 10 μg rCTB or no rCTB. Six mice
from each experimental group were sacriﬁced on day 14, 28 after 1st
immunization and day 14, 28 (day 42, 56) after 2nd immunization and
the serum and nasal wash were collected. The HA speciﬁc antibody of
systemic and mucosal compartments were assessed by indirect ELISA
and hemagglutination inhibition assay. In addition, serum neutraliz-
ing capacity was measured by microneutralization assay. The efﬁcacy
of the vaccine was assessed by host challenge against HPAI H5N1
inﬂuenza strains.
All animal experiments were carried out in accordance with the
Guidelines for Animal Experiments prescribed by National Institute of
Infectious Diseases (NIID) and approved by the Animal Care and Use
Committee of the NIID.
Measurement of anti-H5 HA speciﬁc antibodies by indirect ELISA
The levels of mucosal IgA and serum IgG-speciﬁc antibodies
against rHA0 antigenwere determined separately by indirect enzyme-
linked immunosorbent assay (I-ELISA) according to the method
previously described (Bright et al., 2008). U-bottomed 96-well ELISA
plates were coated with puriﬁed, optimal concentration of 400 ng of
recombinant H5HA in 100 μl of coating buffer (0.1 mol/l carbonate/
bicarbonate, pH 9.6) and incubated overnight at 4 °C. Antigen-coated
plates were washed with PBS containing 0.05% Tween 20 (PBS-T) and
non-speciﬁc sites were blocked with 100 μl blocking buffer (PBS
containing 5% skim milk) for 1 h at 37 °C. Samples of test serum and
mucosal wash were diluted at 1:100 and 1:50 respectively in PBS-T,
and 100 μl was added to triplicate wells and incubated for 1 h at 37 °C
and washed three times with PBS-T. Then, 100 μl of goat anti-mouse
IgG and IgA conjugated with horseradish peroxidise (Sigma, USA)
diluted 1:1000 in PBS were added to the respective wells. The plates
were incubated at 37 °C for 1 h and washed three times with PBS-T.
The plates were then incubated with 100 μL of 3, 3′, 5, 5′-tetramethyl
benzidine (Sigma, USA). The reaction was stopped with 25 μl of 1 M
sulphuric acid and the absorbance was measured at 450 nm using
ELISA plate reader. The mean absorbance value for triplicate wells was
used to express serum antibody level.
Microneutralization assay
The serum neutralizing antibody titers were determined by
microneutralization assay as previously described (Suguitan et al.,
2006). Brieﬂy, MDCK cells were seeded at 1×106 cells/well in 96-well
culture plates and cultured at 37 °C to form amonolayer. Serial two fold
dilutions of heat inactivated (56 °C for 45 min) serum samples were
mixed separately with 100 TCID50 of H5N1 strain incubated at room
temperature for 1 h, and themixturewere added tomonolayerofMDCK
cells in triplicate wells. The neutralizing titers of mouse antiserum that
completely prevented CPE at reciprocal dilutions were calculated.
Hemagglutination inhibition assay
The serum neutralization activity was measured by hemagglutina-
tion inhibition assays (Webster et al., 1991). Receptor destroying
enzyme (RDE) treated (Bright et al., 2006) serawere serially diluted (2
fold) in V-bottom 96-well plates. Approximately 4 HA units of viral
antigen was incubated with the serum for 30 min at room
temperature, followed by the addition of 1% cRBCs and incubation at
room temperature for 40 min. The inhibition of hemagglutination at
the highest serum dilution was considered the HI titer of the serum.
Diseases challenge test against inﬂuenza H5N1 virus infection
Four weeks after the ﬁnal vaccination, mice were anesthetized
with ketamine/xylazine and i.n. infected with 50 μl of 10MLD50(Mouse lethal dose 50%) of two different (CDC/594/Indonesia/06
clade 2.1.2 and TLL/013/Indonesia/06 clade 2.1.3) H5N1 strains. Fifty
percent mouse lethal dose (MLD50) was determined as previously
described by the Reed and Muench (1938) method. To determine the
effect of adjuvant efﬁcacy, animals vaccinated with vaccines without
adjuvant or only with rCTB were also maintained as control groups.
Mice were observed daily to monitor body weight and mortality.
Monitoring continued until all animals died or until day 14 after
challenge.
Statistical analysis
The data are expressed as arithmetic mean±standard error (SE).
The unpaired two tailed Student's t-test was performed to determine
the level of signiﬁcance in the difference between means of two
groups. One way ANOVAwas also used to test for differences between
groups, and Tukey HSD post hoc test was used to determine which
groups were signiﬁcantly different from the rest. All statistical analysis
was done with SigmaStat 2.0 ® (Jandel Corporation) software. The
level of signiﬁcance was expressed as Pb0.05.
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